PHP
FATE icon

Parkman Healthcare Partners’s Fate Therapeutics FATE Stock Holding History

Parkman Healthcare Partners’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-7,615
Closed -$692K – 90
2020
Q4 		$692K Buy
+7,615
New +$473K 0.18% 77

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Parkman Healthcare Partners's FATE Position: Q1 2021 in Review

Parkman Healthcare Partners sold out of Fate Therapeutics (FATE) in Q1 2021, closing a stake of 7,615 shares — an estimated $692K sold.

Parkman Healthcare Partners first reported a position in FATE in Q4 2020 and held it in 1 quarter. The position peaked at $692K in Q4 2020. 260 funds tracked by Wall St. Rank hold FATE as of Q1 2021.

  • Parkman Healthcare Partners reported no remaining Fate Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Parkman Healthcare Partners sold 7,615 Fate Therapeutics shares in Q1 2021, an estimated $692K.
  • Parkman Healthcare Partners first reported a position in Fate Therapeutics in Q4 2020 and held it in 1 quarter.
  • Parkman Healthcare Partners's Fate Therapeutics position peaked at $692K in Q4 2020.
  • 260 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2021.

Based on Parkman Healthcare Partners's 13F filing for Q1 2021, filed 14 May 2021.